Ophthalmic bioanalysis presents unique challenges arising from the eye’s complex anatomy, limited sample volumes, low analyte concentrations, and the difficulty of obtaining true blank matrices. Following topical, intraocular, periocular, or systemic administration, ocular drugs typically exhibit low plasma exposure due to the restrictive blood–ocular barrier, which limits drug penetration into target tissues and results in low systemic concentrations.
Moreover, assessing ocular drug distribution is further complicated by the diverse biochemical composition of tissues such as the cornea, retina, vitreous, and aqueous humor—each yielding only 1–20 µL of sample and requiring picogram-level detection for accurate PK analysis. Each matrix, therefore, demands tailored extraction and processing methods to ensure reliable quantification. Collectively, these factors underscore the need for highly sensitive, well-optimized bioanalytical approaches to support in vivo ophthalmic drug research.
Fit-for-Purpose Ophthalmic Bioanalysis at Meadowhawk Biolabs
At Meadowhawk Biolabs, our Discovery Non-GLP LC-MS methods are tailored to overcome the unique challenges of ocular bioanalysis—micro-scale samples, low analyte levels, and complex tissue matrices.
We apply precision micro-extraction techniques such as optimized micro-LLE or micro-SPE and tissue-specific homogenization to ensure complete drug recovery from 1–5 mg or 1–20 µL samples. Controlled protein precipitation reduces matrix interference for accurate quantification.
Our SCIEX 7500 Triple Quad™ is able to deliver picogram sensitivity, while UPLC (Shimadzu LC40) enables rapid, high-resolution separation to minimize matrix effects and enhance throughput.
To address matrix limitations, we use suitable surrogate matrices and melanin-binding mitigation strategies, ensuring full analyte recovery from pigmented tissues. These integrated workflows provide the sensitivity, reliability, and precision needed to support in vivo ophthalmic drug research.
